trending Market Intelligence /marketintelligence/en/news-insights/trending/8ujqic4iqcmeywbhvpo4bg2 content esgSubNav
In This List

Sosei Group withdraws external director nomination

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sosei Group withdraws external director nomination

Sosei Group Corp. decided to withdraw the nomination of Michael Hayden as an external director.

The appointment had been scheduled for a vote at the company's annual general meeting June 22.

Hayden previously was the global research and development president and chief scientific officer at Teva Pharmaceutical Industries Ltd.

He was nominated, along with Kuniaki Kaga and David Roblin, to provide oversight of the company's research and development pipeline, among other duties.